(IO-102 + IO-103) is under clinical development by IO Biotech and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (IO-102 + IO-103)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(IO-102 + IO-103) overview
PD-L1/IDO (IO102/IO103) peptide vaccine is under development for the treatment of melanoma, metastatic melanoma, head and neck cancer and metastatic non-small cell lung cancer (NSCLC), squamous cell carcinoma of head or neck (SCCHN), metastatic urothelial bladder cancer (mUBC), ureter cancer, kidney cancer (renal cell cancer), bladder cancer, urethral cancer, lung adenocarcinoma, metastatic transitional cell carcinoma (urothelial cell carcinoma), oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer and metastatic solid tumors. It comprises of programmed cell death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase (IDO) peptides. It acts by targeting PD-L1 and IDO. It is developed based on T-win technology. It is administered through subcutaneous route.
It was under development for head and neck cancer and non muscle invasive bladder cancer (NMIBC).
IO Biotech overview
IO Biotech is a biopharmaceutical company that focuses on the development of novel immune-oncology therapies. The company’s primary activity carries out the creation of the T-win vaccine platform, a dual-action immune-modulating cancer vaccine designed to stimulate T cells against tumor cells and immune-suppressive cells in the tumor microenvironment (TME). Its products include its lead investigational candidate IO102-IO103, which combines two T-win vaccines, and IO112, a novel T-win vaccine candidate. IO Biotech’s products target and combat various types of solid tumors and immune-suppressive cells overexpressing specific proteins. The company’s therapies are primarily intended for patients with cancer, including those with difficult-to-treat tumors such as breast, colorectal, pancreatic, prostate, and ovarian cancers. The company operates in the US, Denmark and the UK. IO Biotech is headquartered in Copenhagen, Denmark.
For a complete picture of (IO-102 + IO-103)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.